MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Oragenics Total Current Liabilities 2011-2026 | OGEN
Annual Total Current Liabilities Oragenics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 1.8 M | 1.6 M | 1.45 M | 1.34 M | 1.85 M | 1.17 M | 899 K | 1.34 M | 1.05 M | 796 K | 993 K | 1.26 M | 9.45 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.45 M | 796 K | 1.92 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Ultragenyx Pharmaceutical
RARE
|
384 M | $ 19.23 | -3.85 % | $ 1.9 B |  USA |
 |
ARCA biopharma
ABIO
|
13 M | - | 1052.0 % | $ 415 M | USA |
 |
Regeneron Pharmaceuticals
REGN
|
4.37 B | $ 742.02 | -1.94 % | $ 77.6 B | USA |
 |
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
3.78 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
576 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M | USA |
 |
Replimune Group
REPL
|
62.4 M | $ 7.22 | -4.24 % | $ 582 M | USA |
 |
REGENXBIO
RGNX
|
118 M | $ 7.88 | -4.6 % | $ 406 M | USA |
 |
Aileron Therapeutics
ALRN
|
6.18 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
6.29 M | - | -39.0 % | $ 4.57 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
66.3 M | - | -6.81 % | $ 3.04 B | USA |
 |
Rigel Pharmaceuticals
RIGL
|
99.2 M | $ 26.2 | -0.64 % | $ 471 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
816 K | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
16.3 M | - | -11.76 % | $ 5.79 M | USA |
 |
Avidity Biosciences
RNA
|
195 M | $ 13.09 | -0.08 % | $ 1.8 B | USA |
 |
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
200 M | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
1.93 M | - | 4.01 % | $ 150 M |  Canada |
 |
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
70.6 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
19 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
106 M | $ 78.52 | -4.13 % | $ 5.1 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
89.9 M | $ 12.57 | -9.96 % | $ 1.91 B | USA |
 |
Sana Biotechnology
SANA
|
78.7 M | $ 2.78 | -8.42 % | $ 704 M | USA |
 |
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
SIGA Technologies
SIGA
|
18 M | $ 5.35 | 7.76 % | $ 383 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.47 B | $ 321.71 | -1.96 % | $ 42.1 B | USA |
 |
BioDelivery Sciences International
BDSI
|
82.4 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
25.6 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
63 M | - | - | $ 3.74 B | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
3.8 M | $ 1.08 | -0.92 % | $ 22.2 M | Israel |
 |
Enochian Biosciences
ENOB
|
29.2 M | - | - | $ 40.5 M | USA |